Clinical Trials Logo

Esophageal Neoplasm clinical trials

View clinical trials related to Esophageal Neoplasm.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06348381 Recruiting - Anastomotic Leak Clinical Trials

Prediction of Anastomotic Complications and Recurrent Laryngeal Nerve Injury Based on Postoperative Early Endoscopic Evaluation

Start date: April 1, 2024
Phase:
Study type: Observational

Analyze the correlation between the conformity of the anatomy (based on endoscopic examination) and postoperative anastomotic fistula and anastomotic stenosis; establish an anastomotic classification; and construct a predictive model combined with perioperative-related test indicators to provide more accurate risk assessment for clinical practice. Analyze the natural recovery process of postoperative recurrent laryngeal nerve injury in esophageal cancer by tracking vocal cord movement (based on endoscopic examination) and hoarseness symptoms; combined with perioperative related surgical and laboratory indicators, identify the relevant risk factors associated with delayed recovery of recurrent laryngeal nerve injury.

NCT ID: NCT05453760 Recruiting - Esophageal Neoplasm Clinical Trials

Lung Ultrasound in the Early Detection of Postoperative Pulmonary Complications After Esophagectomy

OESOLUS
Start date: August 21, 2022
Phase:
Study type: Observational

The perioperative management of esophageal cancer has evolved considerably in recent years. Over the last 30 years, postoperative mortality has been steadily decreasing. However, respiratory morbidity remains high (30-40%). This is due to the procedure itself requiring a thoracic approach and intraoperative unipulmonary ventilation. The postoperative pulmonary complications (PPCs) are multiple: bronchial congestion, atelectasis, pneumopathy, acute respiratory distress syndrome (ARDS), liquid pleural effusion, pneumothorax. In general, prevention and early treatment are aimed at limiting the evolution towards acute respiratory failure requiring ventilatory assistance. Chest radiography is essential for the presumptive diagnosis of pneumopathy in particular, but the interpretation of the images may be difficult. Thoracic computed tomography (CT) is the gold standard because it is sensitive and can discriminate among differential diagnoses. This is difficult to perform: it requires intra-hospital transport of patient, who is often in acute respiratory failure, and the availability of an examination area. Lung ultrasound is used at the bedside for diagnosis of lung infection in intensive care unit. This has a sensitivity close to thoracic CT and has the advantage of being feasible at any time, does not require transport of the patient and is not irradiating. Lung ultrasound allows early detection of the need for ventilatory support in postoperative major abdominal surgery . In addition, the sensitivity of lung ultrasound is close to that of CT, allowing this examination to be relied upon. The main objective of the study is to determine the role of lung ultrasound in the prediction of postoperative pulmonary complications within one hour after extubation.

NCT ID: NCT05176002 Recruiting - Radiotherapy Clinical Trials

Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma.

Start date: September 23, 2021
Phase: Phase 1/Phase 2
Study type: Interventional

This is an exploratory phase II clinical study designed to evaluate the safety and efficacy of Camrelizumab in combination with standard radiotherapy as preoperative neoadjuvant therapy for patients with resectable esophageal squamous cell carcinoma. In the study, all subjects who met the enrollment criteria are enrolled after giving full informed consent and signing the enrollment informed consent form, and received radical surgery within 4-8 weeks after completion of neoadjuvant Camrelizumab in combination with standard radiotherapy. The safety evaluation indicators for the study were so adverse events and the number and proportion of subjects who discontinued treatment due to adverse events. The main efficacy indicators of the study were the rate of major pathological remission and the rate of complete pathological remission. A total of 26 cases had to be enrolled in the study. Phase I enrollment was 12 cases, with at least 5 cases achieving efficacy to proceed to Phase II. The trial was considered successful when 14 cases were enrolled in the second phase and the total number of effective cases was greater than 13. The need for postoperative adjuvant treatment and the adjuvant treatment plan were determined by the investigator, and all subjects were required to complete the study's follow-up plan after surgery.

NCT ID: NCT04481100 Recruiting - Clinical trials for Esophageal Squamous Cell Carcinoma

CCRT With Itraconazole in Locally Advanced Squamous Esophageal Cancer

Start date: October 1, 2020
Phase: Phase 2
Study type: Interventional

The objective of this study is to evaluate the efficacy and safety of concurrent chemoradiotherapy combined with Itraconazole in patients with locally adcvanced esophageal squamous cancer

NCT ID: NCT04075305 Recruiting - Breast Cancer Clinical Trials

The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study

MOMENTUM
Start date: February 1, 2019
Phase:
Study type: Observational [Patient Registry]

The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.

NCT ID: NCT02583087 Recruiting - Barrett Esophagus Clinical Trials

ESD for the Treatment of Early Barrett's Neoplasia

ESTEBAN
Start date: January 2, 2016
Phase: N/A
Study type: Observational [Patient Registry]

This study assesses the quality of the resection of early neoplasia arinsing in Barrett's esophagus using endoscopic submucosal dissection. It is a multicenter prospective registry among 7 centers including all consecutive patients with early Barrett's neoplasia of 15 mm or more in size treated by endoscopic submucosal dissection.

NCT ID: NCT00288119 Recruiting - Barrett's Esophagus Clinical Trials

Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma

FBE
Start date: October 1, 2005
Phase:
Study type: Observational

The overall objectives of this BETRNet Research Center (RC) are: 1. to conduct a rigorous, integrated spectrum of transdisciplinary human research in Barrett's esophagus (BE) and esophageal adenocarcinoma (ECA) 2. to increase the biological understanding of key observations made by our clinical researchers; 3. to translate knowledge derived from genetic, epigenetic, and transcriptome research to solving clinical dilemmas in detection, prognosis, prevention, and therapy of BE in order to prevent EAC and improve the outcomes of EAC; 4. to foster a transdisciplinary and translation research culture and to effectively expand and enhance scientific research focused on BE and EAC; 5. to evaluate research and transdisciplinary programs and to continuously improve research, productivity and enhance translational implementation. These objectives build and synergize on existing multi-institutional collaborative networks and the considerable clinical, basic science, and translational expertise available at our institutions, focusing on improving the outcomes of patients with BE and EAC. The overarching organization framework for this RC proposal is 1) to focus laboratory research on understanding the genetic susceptibility, genomic and epigenetic changes that influence the development of BE and EAC; and 2) to then translate laboratorydiscoveries into clinical applications for effective detection, molecular risk stratification, and prevention of progression from BE to EAC.